Purdue Pharma convicted of criminal misbranding over OxyContin

Purdue Pharma’s 2007 criminal misbranding conviction was a landmark federal case over OxyContin, but its negotiated resolution was narrower than the charges prosecutors had considered. Evidence about the drug’s abuse risks had been available before approval; years later, the plea agreement secured a conviction and sentencing while leaving unresolved questions about executive accountability, regulatory oversight, and the wider consequences of opioid promotion.

Evidence and the prosecution’s origins

The case unfolded against evidence that OxyContin’s risks were not wholly unknown at the time of approval. The drug’s 1995 New Drug Application described how crushing a tablet could release the medication immediately rather than gradually, noted withdrawal symptoms during clinical trials, and reported that 68 percent of its oxycodone could be recovered from a single crushed pill after it was liquefied. The application’s reviewer, Curtis Wright, advised caution in promotional materials. Purdue Pharma later claimed it did not know of the drug’s abuse problems until February 2000; Wright subsequently worked as a consultant for the company.

As the federal case developed, prosecutors considered charges beyond misbranding, including mail fraud, wire fraud, and money laundering. By fall 2006, a memorandum indicated that the small-town prosecution team might have assembled enough evidence to charge the company and its senior executives with multiple felonies. The prospect of a jury trial in western Virginia carried particular weight: OxyContin’s problems had become widely known in the region where the case was being pursued.

Negotiations and the plea agreement

The eventual resolution reflected an extended contest over the charges and the penalty. Purdue Pharma initially offered $10 million, while the government’s initial proposal was $1 billion. As the case moved through the U.S. Department of Justice, the proposed charges were reduced, and the executives were not indicted on the felony counts prosecutors had contemplated. Rudy Giuliani, representing the company, lobbied against felony indictments. In 2005, Purdue’s lawyers had also raised concerns about John Brownlee’s investigative methods with then–Deputy Attorney General James Comey, who contacted Brownlee; Brownlee went to Washington to explain his strategy and was told to return to Virginia and proceed.

The last pressure came on the night the plea agreement was due to expire in October 2006. At a Purdue lawyer’s request, a senior Justice Department official called Brownlee at home to urge an extension. Brownlee declined to prolong the negotiations. Later that night, facing the prospect of charges if the deadline passed, Purdue Pharma accepted the agreement rather than risk a trial and more serious charges. Eight days afterward, Brownlee found his name on a list of U.S. attorneys slated for dismissal alongside four others. He was not ultimately fired, but the episode intensified criticism that the attorney general’s office might be trying to influence U.S. attorneys’ work. The company’s defense lawyer, Mary Jo White, had pressed for the extension through a call to a Justice Department official.

Sentencing and the limits of accountability

In 2007, the company and three top executives were sentenced for criminal misbranding. The conviction established a federal consequence for the company’s conduct, but the prosecution’s outcome was more limited than the wider set of felony charges and the initial penalty sought by the government. The negotiations therefore became part of the case’s significance: accountability was achieved, yet the path to it showed how a corporate defendant could contest the scope and cost of a settlement through prolonged legal and political pressure.

The case also sat within a disputed system of drug regulation. In 2013, reporting revealed that FDA regulators and pharmaceutical executives had been meeting privately at expensive hotels at least annually since 2002 through an industry-funded nonprofit. Those meetings contributed to the development of enriched enrollment, a method that allowed companies to exclude study participants who did not respond well to a drug, a practice criticized for tilting approval decisions away from the full evidence. Separate reporting found that the American Pain Society and the American Academy of Pain Medicine had promoted expanded opioid use for long-term chronic pain while receiving millions from drug companies. A 2012 Senate investigation examined ties involving the American Pain Foundation, Purdue, and other organizations and companies, but its findings remained sealed in the Senate Finance Committee’s office.

Aftermath and wider significance

The conviction did not close the legal or public-health debate. Eight years after the sentencing, lawsuits against Purdue and other opioid manufacturers and distributors were being filed by cities, states, and counties. West Virginia and Kentucky had already obtained settlements of $10 million and $24 million, respectively, prompting comparisons with the tobacco litigation that produced a much larger, continuing source of state funding for prevention and public-health programs. The comparison had limits: opioids have legitimate medical uses when properly prescribed, and manufacturers could point to illegal abuse and diversion by people facing economic distress. That distinction complicated efforts to impose accountability without eliminating access to pain treatment or foreclosing future claims.

The case’s significance is also sharpened by the unequal distribution of drug enforcement. In the broader crisis, the appeal to stop relying on arrests was applied most readily to largely white opioid users, while people of color remained disproportionately represented among drug offenders facing imprisonment. The conviction addressed corporate misbranding, but it did not itself resolve the divide between treating addiction as a public-health problem and punishing drug activity through the criminal-justice system.